JP2018526981A - ヒト化またはキメラｃｄ３抗体 - Google Patents

ヒト化またはキメラｃｄ３抗体 Download PDF

Info

Publication number
JP2018526981A
JP2018526981A JP2018501159A JP2018501159A JP2018526981A JP 2018526981 A JP2018526981 A JP 2018526981A JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018526981 A JP2018526981 A JP 2018526981A
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr2
cdr1
cdr3 sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018501159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526981A5 (OSRAM
Inventor
リック ラーデメイカー
リック ラーデメイカー
イシル アルティンタス
イシル アルティンタス
パトリック エンジェルバーツ
パトリック エンジェルバーツ
ジャニーヌ シュールマン
ジャニーヌ シュールマン
ポール パレン
ポール パレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/050296 external-priority patent/WO2016110576A1/en
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2018526981A publication Critical patent/JP2018526981A/ja
Publication of JP2018526981A5 publication Critical patent/JP2018526981A5/ja
Priority to JP2021168124A priority Critical patent/JP7604351B2/ja
Priority to JP2024216521A priority patent/JP2025038049A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018501159A 2015-07-15 2016-07-14 ヒト化またはキメラｃｄ３抗体 Pending JP2018526981A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021168124A JP7604351B2 (ja) 2015-07-15 2021-10-13 ヒト化またはキメラｃｄ３抗体
JP2024216521A JP2025038049A (ja) 2015-07-15 2024-12-11 ヒト化またはキメラｃｄ３抗体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA201500413 2015-07-15
DKPA201500413 2015-07-15
DKPA201500414 2015-07-15
DKPA201500414 2015-07-15
DKPA201500416 2015-07-16
DKPA201500416 2015-07-16
EPPCT/EP2016/050296 2016-01-08
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20
PCT/EP2016/066845 WO2017009442A1 (en) 2015-07-15 2016-07-14 Humanized or chimeric cd3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021168124A Division JP7604351B2 (ja) 2015-07-15 2021-10-13 ヒト化またはキメラｃｄ３抗体

Publications (2)

Publication Number Publication Date
JP2018526981A true JP2018526981A (ja) 2018-09-20
JP2018526981A5 JP2018526981A5 (OSRAM) 2019-08-29

Family

ID=57757079

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018501159A Pending JP2018526981A (ja) 2015-07-15 2016-07-14 ヒト化またはキメラｃｄ３抗体
JP2021168124A Active JP7604351B2 (ja) 2015-07-15 2021-10-13 ヒト化またはキメラｃｄ３抗体
JP2024216521A Pending JP2025038049A (ja) 2015-07-15 2024-12-11 ヒト化またはキメラｃｄ３抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021168124A Active JP7604351B2 (ja) 2015-07-15 2021-10-13 ヒト化またはキメラｃｄ３抗体
JP2024216521A Pending JP2025038049A (ja) 2015-07-15 2024-12-11 ヒト化またはキメラｃｄ３抗体

Country Status (14)

Country Link
US (4) US11359015B2 (OSRAM)
EP (1) EP3322727A1 (OSRAM)
JP (3) JP2018526981A (OSRAM)
KR (2) KR20250048113A (OSRAM)
CN (3) CN120842408A (OSRAM)
AU (2) AU2016293073B2 (OSRAM)
BR (1) BR112018000696A2 (OSRAM)
CA (1) CA2992380A1 (OSRAM)
EA (1) EA201890305A1 (OSRAM)
IL (2) IL256562B2 (OSRAM)
MX (2) MX395317B (OSRAM)
NZ (1) NZ739028A (OSRAM)
UA (1) UA128057C2 (OSRAM)
WO (1) WO2017009442A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536247A (ja) * 2019-06-07 2022-08-15 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
JP2023517753A (ja) * 2020-03-18 2023-04-26 ジェンマブ エー／エス Ｂ７ｈ４に結合する抗体
JP2023547329A (ja) * 2020-10-02 2023-11-10 ジェンマブ エー／エス Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
NZ715896A (en) 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
IL322509A (en) * 2017-03-09 2025-10-01 Genmab As Antibodies against PD-L1
WO2018208877A1 (en) * 2017-05-09 2018-11-15 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
KR20210063351A (ko) * 2018-08-28 2021-06-01 암브룩스, 인코포레이티드 항-cd3 항체 폴레이트 생체접합체 및 이들의 용도
US20220280618A1 (en) * 2019-07-29 2022-09-08 The Administrators Of The Tulane Educational Fund Antibodies to candida and uses thereof
EP4028424A1 (en) 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
IL297986A (en) * 2020-05-08 2023-01-01 Genmab As Bispecific antibodies against cd3 and cd20
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
BR112023004321A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um sujeito humano
KR20240004949A (ko) 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
MX2024003615A (es) * 2021-10-08 2024-04-09 Genmab As Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
CN115368446B (zh) * 2022-07-19 2025-08-08 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001085A1 (en) * 2013-07-05 2015-01-08 Genmab B.V. Humanized or chimeric cd3 antibodies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
RU2561457C2 (ru) 2007-04-03 2015-08-27 Эмджен Рисерч (Мьюник) Гмбх Cd3-эпсилон-связывающий домен с межвидовой специфичностью
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20140170149A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
BR112013029893A2 (pt) 2011-05-21 2017-05-30 Macrogenics Inc molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
CN104822704B (zh) * 2012-06-14 2020-02-14 医疗生物科学有限公司 针对分化簇3(cd3)的人源化的抗体
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
ES2744267T3 (es) 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015001085A1 (en) * 2013-07-05 2015-01-08 Genmab B.V. Humanized or chimeric cd3 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 32, JPN5018005032, 2002, pages 3102 - 3107, ISSN: 0004526195 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536247A (ja) * 2019-06-07 2022-08-15 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
JP7774447B2 (ja) 2019-06-07 2025-11-21 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
JP2023517753A (ja) * 2020-03-18 2023-04-26 ジェンマブ エー／エス Ｂ７ｈ４に結合する抗体
JP7749575B2 (ja) 2020-03-18 2025-10-06 ジェンマブ エー／エス Ｂ７ｈ４に結合する抗体
JP2023547329A (ja) * 2020-10-02 2023-11-10 ジェンマブ エー／エス Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体

Also Published As

Publication number Publication date
US20220389101A1 (en) 2022-12-08
CA2992380A1 (en) 2017-01-19
CN108368172A (zh) 2018-08-03
CN114989302A (zh) 2022-09-02
KR102786353B1 (ko) 2025-03-26
MX2022011002A (es) 2022-10-07
US20220380464A1 (en) 2022-12-01
IL256562B2 (en) 2024-07-01
AU2023201733A1 (en) 2023-07-13
EA201890305A1 (ru) 2018-07-31
CN114989302B (zh) 2025-08-05
WO2017009442A1 (en) 2017-01-19
MX2018000347A (es) 2018-03-14
KR20250048113A (ko) 2025-04-07
AU2016293073B2 (en) 2022-12-22
JP7604351B2 (ja) 2024-12-23
IL256562A (en) 2018-02-28
IL256562B1 (en) 2024-03-01
IL310467A (en) 2024-03-01
CN108368172B (zh) 2022-06-14
US20190284278A1 (en) 2019-09-19
CN120842408A (zh) 2025-10-28
MX395317B (es) 2025-03-25
KR20180030635A (ko) 2018-03-23
NZ778208A (en) 2025-05-02
US11359015B2 (en) 2022-06-14
AU2016293073A1 (en) 2018-02-01
NZ739028A (en) 2023-05-26
US20230027394A1 (en) 2023-01-26
UA128057C2 (uk) 2024-03-27
JP2022023862A (ja) 2022-02-08
JP2025038049A (ja) 2025-03-18
EP3322727A1 (en) 2018-05-23
NZ778205A (en) 2025-05-02
BR112018000696A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
JP7604351B2 (ja) ヒト化またはキメラｃｄ３抗体
JP7757247B2 (ja) ヒト化またはキメラｃｄ３抗体
HK40081214A (en) Humanized or chimeric cd3 antibodies
HK40035360A (en) Humanized or chimeric cd3 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210614

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210730